A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis

Trial Profile

A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Ajulemic acid (Primary)
  • Indications Systemic scleroderma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Corbus Pharmaceuticals
  • Most Recent Events

    • 08 Nov 2017 Results (n=36) of Part B- Open-Label Extension of the trial presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 08 Nov 2017 According to a Corbus Pharmaceuticals media release, company will report 12-month data from the open-label extension study in mid-2018.
    • 06 Nov 2017 According to a Corbus Pharmaceuticals media release, 6-month safety and efficacy data from the open-label extension portion of this trial were presented at the American College of Rheumatology (ACR) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top